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Background
Rheumatoid arthritis (RA) is a chronic, disabling inflam-
matory disease. Tumor necrosis factor (TNF) and inter-
leukin-6 (IL-6) are key elements in the disease pathway
and constitute the target of the most commonly used
biological drugs. Infliximab, adalimumab, etanercept and
golimumab are TNF inhibitors and tocilizumab is an
IL-6-receptor antagonist.
The aim of this work was to assess comparative effec-
tiveness of biological drugs for RA patients registered in
Reuma.pt, using different validate tools.
Methods
We included RA first biological therapy users. Our pri-
mary outcome was EULAR good response at 6 months.
Secondary outcomes were the proportion of patients in
remission applying DAS28, CDAI and SDAI. Groups were
compared using a multivariate logistic model.
Results
520 RA patients. 123 treated with adalimumab, 204 eta-
nercept, 31 golimumab, 110 infliximab and 52 with tocili-
zumab. Mean age at biologics start was 54.4 ± 12.5 years
and disease duration of 11.2 ± 9.6 years. 86.9% were
females and 83.0% were either rheumatoid factor or
ACPA seropositive. Baseline DAS was 5.3 ± 1.2 for adali-
mumab, 5.6 ± 1.2 for etanercept, 5.4 ± 1.3 for golimumab,
5.6 ± 1.3 for infliximab and 5.7 ± 1.2 for tocilizumab
groups (p=0.12 ANOVA). At 6 months, DAS was 3.7 ±
1.3 for adalimumab, 3.8±1.3 for etanercept, 3.5±1.3 for
golimumab, 3.7 ± 1.4 for infliximab and 1.6 ± 0.99 for toci-
lizumab groups (p<0.0001 ANOVA). The probability of
achieving EULAR good response at 6 months was
modeled. Significantly higher rate of good response at 6
months was observed in tocilizumab compared to other
groups with the exception of golimumab. DAS28 remis-
sion threshold was attained by a significantly higher num-
ber of patients treated with tocilizumab. Remission rates
assessed by CDAI and SDAI did not show significant dif-
ferences between groups.
Conclusions
Tocilizumab demonstrated the best efficacy, but the differ-
ence varied with the disease activity tool chosen. These
results reflect the importance of the tool used in the
assessment of treatment response and may be explained
by the pronounced effect of tocilizumab on the reduction
of erythrocyte sedimentation rate, considered only by
DAS28 and not by the other scores.
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